Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NAD(P)H pyrophosphatase NUDT13, mitochondrial (NUDT13) is a mitochondrial enzyme belonging to the Nudix hydrolase family[1][3][6][7]. It preferentially hydrolyzes reduced pyridine nucleotides, specifically NADH to NMNH and AMP, and NADPH to NMNH and 2',5'-ADP, with much lower activity towards other nucleotide substrates[1][3][4]. NUDT13 is targeted to mitochondria via an N-terminal mitochondrial targeting sequence, and functions in the regulation of mitochondrial NADH and NADPH levels as well as the NAD+/NADH and NADP+/NADPH ratios, thereby influencing redox state, energy homeostasis, and potentially responses to oxidative stress[1][3][4][6][7]. Emerging evidence suggests roles in disease processes such as neurodegeneration, ageing, and cancer, including a regulatory influence on epithelial-mesenchymal transition in cancer cells[3]. NUDT13 is part of a highly conserved enzyme family involved in cellular metabolism and nucleotide pool regulation[5]. No drugs, mechanisms of action for inhibitors, pharmacodynamic biomarkers, or specific safety concerns have been described for this target to date.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NAD(P)H pyrophosphatase NUDT13, mitochondrial (NUDT13).